相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
Thomas Yau et al.
INVESTIGATIONAL NEW DRUGS (2013)
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Deprivation of arginine by recombinant human arginase in prostate cancer cells
Eddy C. Hsueh et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis
Tin-Lun Lam et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Pegylated arginase I: a potential therapeutic approach in T-ALL
Claudia P. Hernandez et al.
BLOOD (2010)
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
T-S Yang et al.
BRITISH JOURNAL OF CANCER (2010)
Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)
Sam-Mui Tsui et al.
CANCER CELL INTERNATIONAL (2009)
Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest
T. L. Lam et al.
CANCER LETTERS (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
A New Prognostic Score System in Patients With Advanced Hepatocellular Carcinoma Not Amendable to Locoregional Therapy Implication for Patient Selection in Systemic Therapy Trials
Thomas Yau et al.
CANCER (2008)
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase
Tawnya L. Bowles et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase
Cheol-Yong Yoon et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion
Paul Ning-Man Cheng et al.
CANCER RESEARCH (2007)
A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
W Yeo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma
PNM Cheng et al.
CANCER LETTERS (2005)
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation
BJ Dillon et al.
CANCER (2004)
Controlling cancer by restricting arginine availability - arginine-catabolizing enzymes as anticancer
DN Wheatley
ANTI-CANCER DRUGS (2004)
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies
F Izzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Locoregional therapies for hepatocellular carcinoma: A critical review from the surgeon's perspective
RTP Poon et al.
ANNALS OF SURGERY (2002)
Estimating the world cancer burden: GLOBOCAN 2000
DM Parkin et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
J Bruix et al.
JOURNAL OF HEPATOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)